How Biomarker Testing Helped a Lung Cancer Patient Get the Treatment She NeededUpdates & StatementsLung CancerOncologyResearchScience Will WinTechnology • • •

Earlier this month, Science Will Win, Pfizer's award-winning podcast, wrapped up another successful season. Launched in February, season 6 included five episodes, each one focused on a different aspect of the fight against cancer, wrapping with last week's season finale about AI's impact on cancer care.

All season long, each podcast episode has been accompanied by a full-length video conversation between host Dr. Raven Baxter - a molecular biologist and science educator - and one of her guests, giving you more of the story, more context, and more opportunities to connect beyond the audio episode. You can watch these interviews on Pfizer's YouTube channel here.

In the second episode of the season, which explored biomarkers and precision medicine's role in cancer diagnosis and treatment, Dr. Raven sat down with Kelly Huffman, a longtime healthcare professional, former nurse, and Pfizer employee whose life changed a few days before Christmas 2022. Despite being told she had GERD, allergies, asthma, or even long COVID, Kelly was diagnosed with stage IV non-small cell lung cancer- at only 49 years old.

She shares her story of navigating confusing diagnoses, moments where communication broke down, and how biomarker testing finally revealed her cancer was ALK-positive, changing everything about her treatment. Through it all, Kelly reflects on the value of speaking up for yourself, getting second opinions, and how information can save your life.

Watch the interview below and listen to the "Bringing Cancer into Focus" podcast episode wherever you get your podcasts.